penehyclidine
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
5
Earliest trial started Sep 1, 2014 (NCT02202239)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- penehyclidine
- penehyclidine
- penehyclidine
- penehyclidine hydrochloride
- penehyclidine hydrochloride
- penehyclidine hydrochloride raceme
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06624696 | Phase 4 | Oct 14, 2024 | Shenzhen Eye Hospital, Sun Yat-Sen University |
| NCT04454866 | N/A | Jul 7, 2020 | Peking University |
| NCT04054479 | Phase 4 | Jul 20, 2019 | Nanjing Medical University |
| NCT03868709 | Phase 4 | Nov 10, 2018 | Peking University |
| NCT02644876 | Phase 4 | Sep 1, 2015 | Peking University |
| NCT02202239 | Phase 4 | Sep 1, 2014 | Southern Medical University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 3 | 3 | 2 | 2015 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Shenzhen Eye Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1